Hong Kong · Health Care · HKD (Millions) · Quarterly
Key financials
HKD|Millions
ROE
2.78%
2025 (actual)
ROA
2.4%
2025 (actual)
Gross Margin
83.38%
2025 (actual)
Net Margin
30.4%
2025 (actual)
Total Assets
HK$1,846.70M
2025 (actual)
Net Income
HK$44.26M
2025 (actual)
Valuation
HK$10,696.32M
2025 (actual)
Stock Price
HK$135.90
Historical & projected performance
HKD|Millions
Reported figures and Equlion model projections for the next 12 periods.
ROE
+0.3 pt
Company
ROA
+0.1 pt
Company
Gross Margin
-0.2 pt
Company
Net Margin
-1.1 pt
Company
Total Assets
+10.6%
Company
Amounts in HKD (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for Fujian Haixi Pharmaceuticals Co., Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.